Charles River Laboratories International, Inc., a non-clinical contract research organization, provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The RMS segment produces and sells rodent research model strains and purpose-bred rats and mice for use by researchers. This segment also …
Over the last 12 months, insiders at Charles River Laboratories International, Inc. have bought $0 and sold $16.02M worth of Charles River Laboratories International, Inc. stock.
On average, over the past 5 years, insiders at Charles River Laboratories International, Inc. have bought $1.92M and sold $34.8M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 1,322 shares for transaction amount of $248,298 was made by Girshick Birgit (Corporate Executive VP & COO) on 2023‑11‑20.
2024-11-07 | Sale | director | 7,621 0.0151% | $216.17 | $1.65M | -1.78% | ||
2024-08-08 | Sale | EVP, Corp Strategy & Develop | 1,780 0.0034% | $199.36 | $354,861 | -3.38% | ||
2024-08-01 | Sale | Chairman, President and CEO | 25,000 0.05% | $250.00 | $6.25M | -18.73% | ||
2024-05-15 | Sale | director | 332 0.0007% | $235.62 | $78,225 | -11.52% | ||
2024-05-10 | Sale | EVP, Corp Strategy & Develop | 1,304 0.0025% | $226.97 | $295,969 | -9.54% | ||
2024-03-08 | Sale | CSVP&Chief Accounting Officer | 808 0.0016% | $267.52 | $216,156 | -19.61% | ||
2024-03-04 | Sale | CSVP&Chief Accounting Officer | 2,750 0.0054% | $261.05 | $717,890 | -16.93% | ||
2024-02-29 | Sale | EVP & Chief People Officer | 5,000 0.0097% | $253.70 | $1.27M | -15.16% | ||
2024-02-29 | Sale | CEVP, Disc & Safety Assessment | 3,786 0.0073% | $253.45 | $959,545 | -15.16% | ||
2024-02-22 | Sale | Corporate Executive VP & CCO | 4,050 0.0079% | $248.50 | $1.01M | -12.03% | ||
2024-02-15 | Sale | EVP, Corp Strategy & Develop | 838 0.0016% | $238.93 | $200,223 | -11.07% | ||
2024-02-15 | Sale | CEVP, Disc & Safety Assessment | 5,882 0.0113% | $241.20 | $1.42M | -11.07% | ||
2023-12-14 | Sale | EVP & Chief People Officer | 5,526 0.0106% | $225.00 | $1.24M | -3.38% | ||
2023-11-30 | Sale | EVP, Corp Strategy & Develop | 1,850 0.0036% | $197.73 | $365,801 | +11.29% | ||
2023-11-20 | Corporate Executive VP & COO | 1,322 0.0025% | $187.82 | $248,298 | +14.37% | |||
2023-11-14 | Chairman, President and CEO | 5,620 0.0109% | $178.05 | $1M | +21.69% | |||
2023-11-09 | Sale | EVP, Corp Strategy & Develop | 9,128 0.0182% | $173.48 | $1.58M | +28.79% | ||
2023-08-24 | director | 1,000 0.0019% | $198.79 | $198,786 | +8.50% | |||
2023-08-10 | Sale | EVP, Corp Strategy & Develop | 700 0.0014% | $216.52 | $151,564 | -1.30% | ||
2023-08-10 | Sale | CSVP&Chief Accounting Officer | 1,471 0.0029% | $216.54 | $318,530 | -1.30% |
FOSTER JAMES C | Chairman, President and CEO | 188251 0.3681% | $196.12 | 6 | 84 | +4.13% |
WALLMAN RICHARD F | director | 0 0% | $196.12 | 4 | 13 | +7.27% |
Girshick Birgit | Corporate Executive VP & COO | 44449 0.0869% | $196.12 | 1 | 13 | |
GILLETT NANCY | Corporate Executive VP | 11034 0.0216% | $196.12 | 1 | 41 | +0.49% |
Ho John C | Senior Vice President | 8950 0.0175% | $196.12 | 1 | 0 | +15.04% |
The Vanguard Group | $1.64B | 11.74 | 6.05M | +1.11% | +$17.93M | 0.03 | |
BlackRock | $1.4B | 10.04 | 5.17M | +0.2% | +$2.82M | 0.03 | |
State Street | $567.4M | 4.07 | 2.09M | +1.67% | +$9.3M | 0.02 | |
KAYNE ANDERSON INVESTMENT MANAGEMENT LLC | $508.74M | 3.65 | 1.88M | +7.09% | +$33.7M | 1.18 | |
ClearBridge Investments | $409.98M | 2.94 | 1.51M | +3.07% | +$12.21M | 0.33 |